09:18 AM EDT, 09/24/2025 (MT Newswires) -- Cellectar Biosciences ( CLRB ) and Evestia Clinical said Wednesday they formed a partnership under which Evestia will provide Cellectar with full contract research organization services for an upcoming phase 1b study assessing CLR 125 for the treatment of triple-negative breast cancer.

Cellectar has also chosen a Mayo Clinic Network site as a treatment center for the trial, which is expected to start in Q4, the companies said.

Shares of Cellectar were up over 3% in recent premarket activity.